The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
== Applications == PFBA has a variety of niche applications in analytical and synthetic chemistry. It is an ion pair reagent for reverse-phase high-performance liquid chromatography. It is used in the sequencing, synthesis, and solubilizing of proteins and peptides. Esters derived from PFBA readily undergo condensation, owing to their electrophilicity. Specialized ligands for metal ions are generated capitalizing on this property, such as Eufod. PFBA was formerly used for manufacturing photographic film. The 3M Company was a major manufacturer of PFBA and products containing PFBA but production was phased out in 1998.
== Further reading == Sigel, Roland K. O.; Skilandat, Miriam; Sigel, Astrid; Operschall, Bert P.; Sigel, Helmut (2013). "Chapter 8. Complex formation of cadmium with sugar residues, nucleobases, phosphates, nucleotides and nucleic acids". In Sigel, Astrid; Sigel, Helmut; Sigel, Roland K. O. (eds.). Cadmium: From Toxicology to Essentiality (PDF). Metal Ions in Life Sciences. Vol. 11. Springer. pp. 191–274. doi:10.1007/978-94-007-5179-8_8. ISBN 978-94-007-5178-1. PMID 23430775. Sóvágó, Imre; Várnagy, Katalin (2013). "Chapter 9. Cadmium(II) complexes of amino acids and peptides". In Sigel, Astrid; Sigel, Helmut; Sigel, Roland K. O. (eds.). Cadmium: From Toxicology to Essentiality. Metal Ions in Life Sciences. Vol. 11. Springer. pp. 275–302. doi:10.1007/978-94-007-5179-8_9. ISBN 978-94-007-5178-1. PMID 23430776. Yatsimirsky, Konstantin Borisovich; Vasilyev, Vladimir Pavlovich (1960). Instability Constants of Complex Compounds. Translated by Patterson, D. A. OUP.
Her dissertation work focused on investigating molecular-level surface reactivity and kinetics of metal surfaces using electron spectroscopy, laser desorption, and Fourier transform mass spectrometry techniques. She also designed and built peripheral components for a variable temperature, ultra-high vacuum scanning tunneling microscopy system. In 1997, Caldwell Dyson received the Camille and Henry Dreyfus Postdoctoral Fellowship in Environmental Science to study atmospheric chemistry at the University of California, Irvine. There, she investigated reactivity and kinetics of atmospherically relevant systems using atmospheric pressure ionization mass spectrometry, Fourier transform infrared and ultraviolet absorption spectroscopies. In addition, she developed methods of chemical ionization for spectral interpretation of trace compounds. Caldwell Dyson has published and presented her work in numerous papers at technical conferences and in scientific journals.
Sources: en.wikipedia.org
C.; Schwab, M.; Viegas, M. H.; Roseboom, T. J. (2015). "Prenatal Undernutrition and Leukocyte Telomere Length in Late Adulthood". The American Journal of Clinical Nutrition. 102 (3): 655–660. doi:10.3945/ajcn.115.112326. PMID 26178721. S2CID 4493294. Chen, R.; et al. (2012). "Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes". Cell. 148 (6): 1293–1507. doi:10.1016/j.cell.2012.02.009. PMC 3341616. PMID 22424236. Bernardes De Jesus, B.; Schneeberger, K.; Vera, E.; Tejera, A.; Harley, C. B.; Blasco, M. A. (2011). "The Telomerase Activator TA-65". Aging Cell. 10 (4): 604–621. doi:10.1111/j.1474-9726.2011.00700.x. PMC 3627294. PMID 21426483.
DMF penetrates most plastics and makes them swell. Because of this property DMF is suitable for solid phase peptide synthesis and as a component of paint strippers. DMF is used as a solvent to recover olefins such as 1,3-butadiene via extractive distillation. It is used in the manufacturing of solvent dyes as an important raw material. It is consumed during reaction. Pure acetylene gas cannot be compressed and stored without the danger of explosion. Industrial acetylene is safely compressed in the presence of dimethylformamide, which forms a safe, concentrated solution. The casing is also filled with agamassan, which renders it safe to transport and use. As a cheap and common reagent, DMF has many uses in a research laboratory.
light red or dark pink, being perfused with new capillary loops or "buds"; soft to the touch; moist; bumpy (granular) in appearance, due to punctate hemorrhages; pulsatile on palpation; painless when healthy;
Sources: en.wikipedia.org
Epithelial cells climb over one another in order to migrate. This growing sheet of epithelial cells is often called the epithelial tongue. The first cells to attach to the basement membrane form the stratum basale. These basal cells continue to migrate across the wound bed, and epithelial cells above them slide along as well. The more quickly this migration occurs, the less of a scar there will be. Fibrin, collagen, and fibronectin in the ECM may further signal cells to divide and migrate. Like fibroblasts, migrating keratinocytes use the fibronectin cross-linked with fibrin that was deposited in inflammation as an attachment site to crawl across.
== Discoidin domain receptors == Discoidin domain receptors form a subgroup of receptor tyrosine kinases. Receptor activation happens when collagen binds into preformed DDR dimers on cell membrane, when collagen is bound, a conformational change probably occurs, which causes cytosolic kinases to rotate to face each other, and their autophosphorylation. The exact way of receptor activation is unknown so far. Unlike other tyrosine-kinase receptors, maximal activation of receptors occurs 18 hours after collagen stimulation. They function as receptors for different collagen types, they recognize many fibrillar collagens and they are capable of binding some nonfibrillar collagens as well. Nevertheless, the native conformation of collagen is a requirement for receptor binding, denatured collagen is not bound. DDRs are expressed widely already during development and level of expression is high in adults as well. DDR1 is a homodimer. Its ectodomain consists of a collagen-binding discoidin domain followed by ~200 residues of unknown structure. It binds fibril-forming collagens and primarily type IV collagen, but also collagen of types I, VI, VIII. It is expressed mainly in epithelial cells and leukocytes and expression rate changes due to cell cycle phase. Functions include: mammary gland development; arterial wound repair; regulation of cell proliferation, cell adhesion and MMP expression; kidney function, differentiation and function of leukocytes. DDR2 structure as above. Binds fibril-forming collagens, collagen of types I, II, III and X.
With increased concerns about nuclear waste, breeding fuel cycles came under renewed interest as they can reduce actinide wastes, particularly plutonium and minor actinides such as neptunium, americium and curium. Breeder reactors are designed to fission the actinide wastes as fuel and thus convert them to more fission products. For unreprocessed uranium-oxide spent nuclear fuel, Bodansky's 2006 review described a rapid initial decrease in radioactivity as short-lived fission products decay, followed by a more gradual decrease as actinides decay. Today's commercial light-water reactors do breed some new fissile material, mostly in the form of plutonium. Because commercial reactors were never designed as breeders, they do not convert enough uranium-238 into plutonium to replace the uranium-235 consumed. Nonetheless, at least one-third of the power produced by commercial nuclear reactors comes from fission of plutonium generated within the fuel. Even with this level of plutonium consumption, light water reactors consume only part of the plutonium and minor actinides they produce, and nonfissile isotopes of plutonium build up, along with significant quantities of other minor actinides. Since breeder reactors on a closed fuel cycle would use nearly all of the isotopes of these actinides fed into them as fuel, their fuel requirements would be reduced by a factor of about 100. Waste volume alone does not determine disposal requirements. A 2023 DOE assessment identified radionuclide inventory, heat output, chemical and physical properties, and packaging as relevant factors.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.